Analysts Set Roche Holding AG (OTCMKTS:RHHBY) Price Target at $57.00

Shares of Roche Holding AG (OTCMKTS:RHHBY) have been given a consensus recommendation of “Hold” by the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $57.00.

Several equities research analysts have recently weighed in on RHHBY shares. Barclays raised shares of Roche from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group upgraded shares of Roche from a “sell” rating to a “hold” rating in a report on Thursday, January 15th. JPMorgan Chase & Co. raised shares of Roche from an “underweight” rating to a “neutral” rating in a research note on Monday, December 8th. Citigroup began coverage on Roche in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Finally, Wolfe Research reaffirmed an “outperform” rating on shares of Roche in a research note on Thursday, February 26th.

Roche Price Performance

Shares of RHHBY opened at $49.85 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. Roche has a 52-week low of $34.75 and a 52-week high of $60.85. The business has a fifty day moving average of $54.83 and a 200 day moving average of $49.74.

Institutional Trading of Roche

A number of hedge funds and other institutional investors have recently bought and sold shares of RHHBY. Curio Wealth LLC purchased a new stake in shares of Roche during the third quarter valued at $25,000. Oakworth Capital Inc. purchased a new position in Roche in the 3rd quarter worth about $57,000. Salomon & Ludwin LLC lifted its holdings in Roche by 256.6% during the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after buying an additional 2,053 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in Roche in the 4th quarter valued at about $192,000. Finally, Douglass Winthrop Advisors LLC purchased a new stake in Roche in the 3rd quarter valued at about $201,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.